Product Description
LR20062' is a vaccine that prevents six infections, including diphtheria, tetanus, whooping cough, polio, hemophilus influenzae, and hepatitis B. Compared to the commonly used combination of the pentavalent vaccine and hepatitis B vaccine, the number of inoculations has been reduced by two (6 times → 4 times). (Sourced from: https://www.mk.co.kr/en/it/11091904)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: LG Chem
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|